The research on Fama-French 5-factor model in the medicine industry during COVID-19

Authors

  • Tingyu Sun
  • Yansu Wang
  • Menglong Yang

DOI:

https://doi.org/10.54691/bcpbm.v36i.3388

Keywords:

Fama-French 5-factor model; Medicine industry; COVID-19; Policy Making.

Abstract

During COVID-19, the diease has changed various aspects on the stock market so dramatically that the stock prices in different industry fields. While Fama-French 5-factor model is one of the most effective stock prices assessment models, the worldwide change during these several years could have the unexpected influence on this professional method. In this research, attempting to find the relationship between medicine policy and the stock price, in order to explain the huge change on the economics progress with this model, the linear regression is adopted to cope with this issue. Results indicate that most of the regression coefficients of the explanatory variables under the five factors have the same significance, with only the difference in the size of the coefficient values. Besides, the larger the value of the policy, the higher the risk premiums of pharmaceutical companies will be, additionally, small minus big, high minus low, robust minus weak, and conservative minus aggressive average returns will decrease, and vice versa. In summary, this paper investigates the effectiveness of Fama-French 5-factor model with the new variable, the medicine policy, based on linear regression and other mathematics methods. In the future, it is of great importance to investigate stock prices under such situation and take other factors into seriously account while doing research. Overall, these results shed light on guiding future policy making and different perspective on medicine industry development.

Downloads

Download data is not yet available.

References

C. L. Mann, “Real and Financial Lenses to Assess the Economic Consequences of COVID-19.” Economics in the Time of COVID-19, vol.1, 2020, pp. 81 - 86.

H. Y. Liu, A. Manzoor, C. Y. Wang, et al., “The COVID-19 outbreak and affected countries stock markets response.” International Journal of Environmental Research and Public Health, vol. 17 (8), 2020, 2800.

S. C. Ludvigson, S. Ma, S. Ng, “COVID-19 and The Macroeconomic Effects of Costly Disasters”, COVID-19 and the macroeconomic effects of costly disasters. No. w26987. National Bureau of Economic Research, 2020.

W. Ding, R. Levine, C. Lin, et al., “Corporate Immunity to the COVID-19 Pandemic.” Journal of Financial Economics, vol. 141.2, 2021, pp. 802 - 830.

A. M. Al-Awadhi, et al. "Death and contagious infectious diseases: Impact of the COVID-19 virus on stock market returns." Journal of behavioral and experimental finance, vol. 27, 2020, 100326.

R. M. del Rio-Chanona, et al. "Supply and demand shocks in the COVID-19 pandemic: An industry and occupation perspective." Oxford Review of Economic Policy vol. 36, 2020, pp. 94 - 137.

S. Girish, and K. Desai. "An Analysis of Accounting Variables and its impact on Market price per Share: Evidence from Nifty Pharma Index Companies of India." Asian Journal of Management, vol. 9 (1), (2018, pp. 333 - 336.

E. F. Fama, K. R. French. “Common Risk Factors in the Returns on Stocks and Bonds.” Journal of Economics, vol. 33, 1993, pp. 3 - 56.

E. F. Fama, K. R. French, “Multifactor Explanations of Asset Pricing Anomalies.” Journal of Finance, vol. 51, 1996, pp. 55 - 83.

E. F. Fama, K. R. French "A Five-Factor Asset Pricing Model". Journal of financial economics vol. 116.1, 2015, pp. 1 - 22.

Downloads

Published

2023-01-13

How to Cite

Sun, T., Wang, Y., & Yang, M. (2023). The research on Fama-French 5-factor model in the medicine industry during COVID-19. BCP Business & Management, 36, 77–82. https://doi.org/10.54691/bcpbm.v36i.3388